Cancer Chemother Pharmacol. 1991;28(3):199-204.

Alleviation by leucovorin of the dose-limiting toxicity of edatrexate: potential for improved therapeutic efficacy.

Lee JS, Murphy WK, Shirinian MH, Pang A, Hong WK.

Source

Department of Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030.

Abstract

Edatrexate (10-ethyl-10-deaza-aminopterin; CGP 30 694) is a methotrexate (MTX) analogue that shows promise against non-small-cell lung cancer (NSCLC) and other tumors. Since edatrexate's mechanism of action is the same as that of MTX, we used leucovorin in an attempt to alleviate its dose-limiting toxicity, stomatitis. In four patients with NSCLC who had experienced significant stomatitis after treatment with edatrexate, cyclophosphamide, and cisplatin, we observed a remarkable reduction in stomatitis following the administration of low-dose leucovorin. On the basis of the results obtained in these individuals, we treated 15 additional patients with this three-drug regimen plus leucovorin rescue. These subjects could tolerate the treatment with lesser degrees of stomatitis and received higher edatrexate doses in subsequent courses as compared with the patients who previously received this regimen without leucovorin rescue. This approach is expected to improve the therapeutic indices of edatrexate and edatrexate-containing chemotherapy regimens by modifying the dose-limiting toxicity of this antineoplastic agent.

PMID:: 1649705; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

EBSCO

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non-small cell lung cancer. [Cancer. 1991]
Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non-small cell lung cancer.
Lee JS, Libshitz HI, Fossella FV, Murphy WK, Pang AC, Lippman SM, Shin DM, Dimery IW, Glisson BS, Hong WK. Cancer. 1991 Sep 1; 68(5):959-64.
Review Edatrexate studies in non-small cell lung cancer. [Lung Cancer. 1995]
Review Edatrexate studies in non-small cell lung cancer.
Gralla RJ. Lung Cancer. 1995 Apr; 12 Suppl 1:S187-91.
Improved therapeutic index by leucovorin of edatrexate, cyclophosphamide, and cisplatin regimen for non-small-cell lung cancer. [J Natl Cancer Inst. 1992]
Improved therapeutic index by leucovorin of edatrexate, cyclophosphamide, and cisplatin regimen for non-small-cell lung cancer.
Lee JS, Libshitz HI, Fossella FV, Murphy WK, Pang AC, Lippman SM, Shin DM, Dimery IW, Glisson BS, Hong WK. J Natl Cancer Inst. 1992 Jul 1; 84(13):1039-40.
Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin. [Clin Cancer Res. 2001]
Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
Laurie SA, Pfister DG, Kris MG, Tong WP, Chronowski G, Pisters KM, Heelan RT, Sirotnak FM. Clin Cancer Res. 2001 Mar; 7(3):501-9.
Review Edatrexate, an antifolate with antitumor activity: a review. [Cancer Invest. 1993]
Review Edatrexate, an antifolate with antitumor activity: a review.
Grant SC, Kris MG, Young CW, Sirotnak FM. Cancer Invest. 1993; 11(1):36-45.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Recent activity

Clear Turn Off Turn On

Alleviation by leucovorin of the dose-limiting toxicity of edatrexate: potential...
Alleviation by leucovorin of the dose-limiting toxicity of edatrexate: potential for improved therapeutic efficacy.
Cancer Chemother Pharmacol. 1991 ;28(3):199-204.

PubMed
[Neoplastic angiogenesis and age-related macular degeneration: historic aspects ...
[Neoplastic angiogenesis and age-related macular degeneration: historic aspects of the microcirculation of new vessels].
Recenti Prog Med. 2005 Dec ;96(12):616-20.

PubMed
Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human ...
Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors.
Int J Cancer. 2006 Aug 1 ;119(3):712-7.

PubMed
Angiotensin-converting enzyme: zinc- and inhibitor-binding stoichiometries of th...
Angiotensin-converting enzyme: zinc- and inhibitor-binding stoichiometries of the somatic and testis isozymes.
Biochemistry. 1991 Jul 23 ;30(29):7118-26.

PubMed
Early decompressive craniectomy may be effective in the treatment of refractory ...
Early decompressive craniectomy may be effective in the treatment of refractory intracranial hypertension after traumatic brain injury.
Childs Nerv Syst. 2006 Oct ;22(10):1268-74. Epub 2006 Feb 22 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: